DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Applicant’s amendment filed on 11/03/2025 has been entered.
Claims 1-2, 4-5, 9-10, 14-19, 24, 26, 29-33 and 38 are pending in the present application.
Applicant’s election without traverse of Group I in the reply filed on 11/03/2025 is acknowledged.
Applicant also elected the following species: (i) SEQ ID NO: 1; (ii) a cationic branched synthetic polymer; (iii) a combination of lactic acid and glycolic acid; (iv) about 45 nm to about 700 nm; (v) a polysaccharide coating; and (vi) adeno-associated virus.
Accordingly, claims 29-33 and 38 were withdrawn from further consideration because they are directed to non-elected inventions. Additionally, claim 17 was also withdrawn from further consideration because it is directed to a non-elected species.
Therefore, claims 1-2, 4-5, 9-10, 14-16, 18-19, 24 and 26 are examined on the merits herein with the above elected species.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 18 and 26 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
In claim 18, it is unclear what is encompassed by the limitation “The composition of claim 1 wherein a virus comprises the nucleic acid encoding lubricin”. Apart from containing the nucleic acid encoding lubricin, what is the nexus between a virus and nanoparticles comprising isolated nucleic acid comprising nucleic acid encoding a mammalian lubricin and a cationic polymer? Clarification is requested because the metes and bounds of the claim are not clearly determined.
In claim 26, it is also unclear what is encompassed by the limitation “wherein the virus is combined with nanoparticles”. Combined in which way? The virus is combined with nanoparticles as two separate delivery vehicles or as a single delivery in various forms (e.g., nanoparticles are coated with the virus, the virus is encapsulated within the nanoparticles but it is separated with an isolated nucleic acid comprising nucleic acid encoding a mammalian lubricin and a cationic polymer). Once again, clarification is requested because the metes and bounds of the claim are not clearly determined. For the purpose of a compact prosecution and to be consistent with the specification, the examiner interprets the limitation to be meant that the virus is combined with nanoparticles as two separate delivery vehicles.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 1-2, 4-5, 9-10, 18, 24 and 26 are rejected under 35 U.S.C. 103 as being unpatentable over Sharma et al (WO 2018/067545; IDS) in view of Emans et al (US 2013/0123314; IDS), Ruan et al (WO 2014/115022) and D’Mello et al (The AAPS Journal 19:43-53; 2017).
The instant claims encompass a composition comprising nanoparticles (e.g., formed of lactic acid, glycolic acid, caproic acid, or combination thereof) comprising isolated nucleic acid comprising nucleic acid encoding a mammalian lubricin/PRG4 (e.g., a lubricin having at least 80% amino acid sequence identity to the elected SEQ ID NO: 1) and a cationic polymer (e.g., a linear or branched synthetic polymer comprising polybrene or polyethyleneimine); the same composition further comprising a virus comprising the nucleic acid encoding lubricin in combination with the nanoparticles.
With respect to the elected species, Sharma et al already taught at least chondroprotective nanoparticles into the extracellular matrix (ECM) of tissues, such as degenerating cartilage, to provide local and sustained release of drugs/therapeutic agents for the treatment of osteoarthritis (e.g., post-traumatic osteoarthritis), wherein the nanoparticles are biodegradable and formed from any natural or synthetic biocompatible polymer, and the nanoparticles comprises a therapeutic agent (e.g., Kartogenin (KGN), PDGF-BB, antioxidants, anti-catabolic agents, anabolic agents and anti-inflammation agents) encapsulated therein (Abstract; Summary; particularly page 16, line 18 continues to line 23 at page 18). Sharma et al stated “In some embodiments, the nanoparticles are formed from a polymer selected from the group consisting of hyaluronan, chitosan, collagen, gelatin, alginate, polylactic acid (PLLA), polyglycolic acid (PGA), poly(lactic-co-glycolic acid) (PLGA), poly(ethylene glycol), and chondroitin sulfate” (page 3, lines 15-20); and “The disclosed delivery system can involve nanoparticles that are limited in size from about 5 nanometers to about 750 nanometers, including about 10 to about 500 nanometers, about 20 to about 200 nanometers, and about 30 nanometers to about 100 nanometers” (page 16, lines 19-22). In a particular/preferred embodiment, Sharma et al disclosed the nanoparticle has a mean diameter ranging from 30 nm to 300 nm (page 3, lines 11-13). Sharma et al also defined the term “agent” to include modified and unmodified nucleic acids, with a nucleic acid as an active agent (page 9, lines 16-28); and anti-cancer therapeutic agents include DNA such as plasmid DNA for wild type p53 for delivering into the ECM of tumor margins using the disclosed nanoparticles (Abstract; and page 12, lines 14-16). Sharma et al also taught that KGN is a small molecule having chondrogenic and chondroprotective effects, and it has been demonstrated to induce lubricin/Prg4 expression (page 26, lines 31-35).
Sharma et al did not teach explicitly that the chondroprotective nanoparticles (e.g., elected species of the combination of lactic acid and glycolic acid, such as PLGA) comprising a nucleic acid encoding a mammalian lubricin and a cationic polymer (e.g., elected species of a linear or branched synthetic polymer such as one comprising polyethyleneimine (PEI)).
Before the effective filing date of the present application (10/28/2019), Emans already taught to deliver at least agents/drugs that enhance lubrication of a joint such as hyaluronan and/or superficial zone protein (SZP)/lubricin inside a biodegradable and biocompatible release system that will slowly release the enclosed drugs for improving cartilage repair and/or slowing down of cartilage degeneration (Abstract; Summary of the Invention; particularly paragraphs [0039]-[0040], [0065] and [0081]). Emans et al also stated “The invention may also be practiced with other release systems which have been described. Some non-limiting examples of such systems include microspheres, liposomes, alone or in combination with the above described biogels and hydrogels” (paragraph [0082]).
Additionally, Ruan et al already disclosed at least one helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian proteoglycan 4 (PRG4) for use in the treatment of a musculoskeletal disorder such as osteoarthritis and rheumatoid arthritis (Abstract; Summary of the Invention; and pages 14-16). Ruan et al stated “[t]he helper-dependent adenoviral vector comprising proteoglycan 4 (PRG4) comprises a nucleic acid sequence set forth in SEQ ID NO 1 (human HDAd) or SEQ ID NO 2 (murine HDAd). Preferably, the nucleic acid sequence comprises a cDNA sequence of the PRG4 gene or a fragment thereof” (page 6, lines 26-29). The sequence of nucleotides 28157-32368 in SEQ ID NO 1 encodes the amino acid sequence that is 100% identical to SEQ ID NO: 1 of the present application (see attached sequence search below).
Moreover, in a review of bone regeneration and soft tissue healing (e.g., blood vessels, cartilage, muscles, ligaments and tendons) using gene-activated matrices (GAM) D’Mello et al stated “In spite of lower transfection efficiencies compared to that of viral vectors, non-viral vectors are safer and can be clinically translated for potential bone regeneration applications” (page 46, left column, second last paragraph); and “pDNA can be complexed via electrostatic interactions with liposomes, polymers, or other polycations to form either lipoplexes or polyplexes. Among the numerous non-viral gene vectors studied in vitro and in vivo, polyethylenimine (PEI), especially the branched 25-kDa PEI polymer, is one of the most successful gene transfer agents to date (40). PEI is believed to exhibit higher transfection efficiencies than many other non-viral vectors due to a phenomenon known as the “proton sponge effect” (41) and the level of transfection efficiency attained with PEI is considered comparable with that of viral vectors” (page 46, right column, bottom of first paragraph). Table III lists different types of GAMs for induction of bone formation, including the PLGA scaffold containing PEI-pDNA complexes, wherein the pDNA comprises a sequence encoding BMP-4 (section titled “Hard tissue regeneration with a focus on the use of GAMs” on page 49; and Table III on page 50).
Accordingly, it would have been obvious for an ordinary skill in the art to modify the teachings of Sharma et al by also selecting at least a nucleic acid encoding a mammalian lubricin having SEQ ID NO: 1 in the form of a recombinant pDNA-PEI polyplex as a therapeutic agent encapsulated within the disclosed chondroprotective nanoparticles (including nanoparticles having an average diameter of about 450 nm to about 700 nm) for sustained release of the therapeutic agent in the treatment of osteoarthritis and/or post-traumatic osteoarthritis, as well as further including into the composition a recombinant virus comprising a nucleic acid encoding the same mammalian lubricin; in light of the teachings of Emans et al, Ruan et al and D’Mello et al as presented above.
An ordinary skill in the art would have been motivated to carry out the above modifications because: (i) Emans already taught to deliver at least agents/drugs that enhance lubrication of a joint such as hyaluronan and/or superficial zone protein (SZP)/lubricin inside a biodegradable and biocompatible release system that will slowly release the enclosed drugs for improving cartilage repair and/or slowing down of cartilage degeneration; (ii) Ruan et al already taught successfully at least the use of helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian proteoglycan 4 (PRG4), including a nucleic acid sequence set forth in SEQ ID NO 1 (human HDAd), for use in the treatment of a musculoskeletal disorder such as osteoarthritis and rheumatoid arthritis; and (iii) D’Mello et al already taught that non-viral vectors are safer relative to viral vectors, and pDNA can be complexed via electrostatic interactions with polymers, or other polycations to form polyplexes; and among the numerous non-viral gene vectors studied in vitro and in vivo, polyethylenimine (PEI), especially the branched 25-kDa PEI polymer, is one of the most successful gene transfer agents to date that exhibits higher transfection efficiencies than many other non-viral vectors due to a phenomenon known as the “proton sponge effect” and the level of transfection efficiency attained with PEI is considered comparable with that of viral vectors. Please also note that the primary Sharma reference also taught using the disclosed nanoparticles for delivering into the ECM of tumor margins a cancer therapeutic agent such as plasmid DNA for wild type p53. With respect to the limitation of “wherein the nanoparticles have an average diameter of about 450 nm to about 700 nm” in claim 10, the primary Sharma reference also taught at least that the disclosed delivery system can involve nanoparticles that are limited in size from about 5 nanometers to about 750 nanometers, including about 10 to about 500 nanometers.
An ordinary skilled artisan would have a reasonable expectation of success in light of the teachings of Sharma et al, Emans et al, Ruan et al and D’Mello et al; coupled with a high level of skill for an ordinary skilled artisan in the relevant art.
The modified composition resulting from the combined teachings of Sharma et al, Emans et al, Ruan et al and D’Mello et al as set forth above is indistinguishable and encompassed by the presently claimed invention.
Therefore, the claimed invention as a whole was prima facie obvious in the absence of evidence to the contrary.
Claim 24 (elected adeno-associated virus embodiment) is rejected under 35 U.S.C. 103 as being unpatentable over Sharma et al (WO 2018/067545; IDS) in view of Emans et al (US 2013/0123314; IDS), Ruan et al (WO 2014/115022) and D’Mello et al (The AAPS Journal 19:43-53; 2017) as applied to claims 1-2, 4-5, 9-10, 18, 24 and 26 above, and further in view of Dias Figueiredo et al (US 11,905,531).
The combined teachings of Sharma et al, Emans et al, Ruan et al and D’Mello et al were presented above. However, none of the cited references teach explicitly the use of an adeno-associated virus comprising a nucleic acid encoding a mammalian lubricin.
Before the effective filing date of the present application (10/28/2019), Dias Figueiredo et al already taught recombinant AAV vectors/virus expressing osteoprotective genes, including HAS2 and Lubricin (PRG4) such as a full-length canine lubricin cDNA, that are useful in the treatment of osteoarthritis and related joint conditions in mammals (see at least Abstract; col. 2, line 64 continues to line 28 at column 3; col. 4, lines 28-46; and Example 2). Dias Figueiredo et al stated “[t]he rAAV vectors encode lubricin or a variant thereof. In some embodiments, the lubricin is human lubricin. In other embodiments, the lubricin is canine lubricin” (col. 4, lines 28-31). Dias Figueiredo et al also disclosed the nucleic acid sequence of SEQ ID NO: 12, in which the sequence of nucleotides 52-4263 encodes the amino acid sequence that is 100% identical to SEQ ID NO: 1 of the present application (see col. 18, lines 10-19; Figs. 15-16; and attached sequence search below).
Accordingly, it would have been obvious for an ordinary skill in the art to further modify the combined teachings of Sharma et al, Emans et al, Ruan et al and D’Mello et al by also further using an adeno-associated virus comprising a nucleic acid encoding a mammalian lubricin, in light of the teachings of Dias Figueiredo et al as presented above.
An ordinary skill in the art would have been motivated to further carry out the above modification because Dias Figueiredo et al already taught successfully using a recombinant AAV vectors/virus expressing Lubricin (PRG4) such as a full-length canine lubricin cDNA, that is useful in the treatment of osteoarthritis and related joint conditions in mammals.
An ordinary skilled artisan would have a reasonable expectation of success in light of the teachings of Sharma et al, Emans et al, Ruan et al, D’Mello et al and Dias Figueiredo et al; coupled with a high level of skill for an ordinary skilled artisan in the relevant art.
The modified composition resulting from the combined teachings of Sharma et al, Emans et al, Ruan et al, D’Mello et al and Dias Figueiredo et al as set forth above is indistinguishable and encompassed by the presently claimed invention.
Therefore, the claimed invention as a whole was prima facie obvious in the absence of evidence to the contrary.
Claims 14-16 are rejected under 35 U.S.C. 103 as being unpatentable over Sharma et al (WO 2018/067545; IDS) in view of Emans et al (US 2013/0123314; IDS), Ruan et al (WO 2014/115022) and D’Mello et al (The AAPS Journal 19:43-53; 2017) as applied to claims 1-2, 4-5, 9-10, 18, 24 and 26 above, and further in view of Wang et al (AAPS Pharm Sci Tech 15:585-592, 2013).
The combined teachings of Sharma et al, Emans et al, Ruan et al and D’Mello et al were presented above. However, none of the cited references teach explicitly that the nanoparticles comprise a coating, preferably with the elected chitosan as a polysaccharide coating.
Before the effective filing date of the present application (10/28/2019), Wang et al already taught chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery (Abstract and Figure 1). Wang et al stated “The chitosan on PLGA nanoparticles surface affected the drug release profile. The positive charge and hydrophilic property induced a moderate and prolonged drug release and a high cumulative drug release” (page 591, right column, first full paragraph in the “Conclusions” section).
Accordingly, it would have been obvious for an ordinary skill in the art to further modify the combined teachings of Sharma et al, Emans et al, Ruan et al and D’Mello et al by also coating their PLGA nanoparticles with chitosan for improving drug delivery, in light of the teachings of Wang et al as presented above.
An ordinary skill in the art would have been motivated to further carry out the above modification because Wang et al already taught successfully that chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery.
An ordinary skilled artisan would have a reasonable expectation of success in light of the teachings of Sharma et al, Emans et al, Ruan et al, D’Mello et al and Wang et al; coupled with a high level of skill for an ordinary skilled artisan in the relevant art.
The modified composition resulting from the combined teachings of Sharma et al, Emans et al, Ruan et al, D’Mello et al and Wang et al as set forth above is indistinguishable and encompassed by the presently claimed invention.
Therefore, the claimed invention as a whole was prima facie obvious in the absence of evidence to the contrary.
Claim 19 is rejected under 35 U.S.C. 103 as being unpatentable over Sharma et al (WO 2018/067545; IDS) in view of Emans et al (US 2013/0123314; IDS), Ruan et al (WO 2014/115022) and D’Mello et al (The AAPS Journal 19:43-53; 2017) as applied to claims 1-2, 4-5, 9-10, 18, 24 and 26 above, and further in view of Bain et al (WO 2018/048942).
The combined teachings of Sharma et al, Emans et al, Ruan et al and D’Mello et al were presented above. However, none of the cited references teach explicitly that the composition further comprising an anti-fibrotic agent.
Before the effective filing date of the present application (10/28/2019), Bain et al already taught using a lysyl oxidase like 2 (LOXL2) inhibitor, an antifibrotic agent, for treating at least osteoarthritis and rheumatoid arthritis (Abstract; Summary of the Invention; particularly paragraphs [0033]-[0036], [0065], [0071], [00253]-[00256], [00259]; and claims 64-65). Bain et al disclosed that fibrosis refers to the accumulation of extracellular matrix constituents that occurs following trauma, inflammation, tissue repair, immunological reactions, cellular hyperplasia, and neoplasia (paragraph [0071]); and LOXL2 is involved in fibrotic processes (paragraph [0065]). Bain et al stated “Osteoarthritis (OA) is a type of joint disease that results from breakdown of joint cartilage and underlying bone. LOXL2 has been shown to be highly expressed in the damaged region of OA cartilage” (first sentence of paragraph [00259]).
Accordingly, it would have been obvious for an ordinary skill in the art to further modify the combined teachings of Sharma et al, Emans et al, Ruan et al and D’Mello et al by also further including at least a LOXL2 inhibitor into the composition for the treatment of osteoarthritis, in light of the teachings of Bain et al as presented above.
An ordinary skill in the art would have been motivated to further carry out the above modification because Bain et al already taught using a lysyl oxidase like 2 (LOXL2) inhibitor, an antifibrotic agent, for treating at least osteoarthritis.
An ordinary skilled artisan would have a reasonable expectation of success in light of the teachings of Sharma et al, Emans et al, Ruan et al, D’Mello et al and Bain et al; coupled with a high level of skill for an ordinary skilled artisan in the relevant art.
The modified composition resulting from the combined teachings of Sharma et al, Emans et al, Ruan et al, D’Mello et al and Bain et al as set forth above is indistinguishable and encompassed by the presently claimed invention.
Therefore, the claimed invention as a whole was prima facie obvious in the absence of evidence to the contrary.
Conclusions
No claim is allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Quang Nguyen, Ph.D., at (571) 272-0776.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s acting SPE, James Douglas (Doug) Schultz, Ph.D., may be reached at (571) 272-0763.
To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1631; Central Fax No. (571) 273-8300.
Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.
Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO’s Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll-free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO’s Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO’s PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.
/QUANG NGUYEN/Primary Examiner, Art Unit 1631
Human PRG4 gene containing HDAd vector DNA, SEQ ID 1.
WO2014115022-A1.
Alignment Scores:
Length: 33136
Score: 7516.00 Matches: 1403
Percent Similarity: 99.9% Conservative: 0
Best Local Similarity: 99.9% Mismatches: 1
Query Match: 99.9% Indels: 0
Gaps: 0
US-17-772-450-1 (1-1404) x BBL00108 (1-33136)
Qy 1 MetAlaTrpLysThrLeuProIleTyrLeuLeuLeuLeuLeuSerValPheValIleGln 20
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28157 ATGGCATGGAAAACACTTCCCATTTACCTGTTGTTGCTGCTGTCTGTTTTCGTGATTCAG 28216
Qy 21 GlnValSerSerGlnAspLeuSerSerCysAlaGlyArgCysGlyGluGlyTyrSerArg 40
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28217 CAAGTTTCATCTCAAGATTTATCAAGCTGTGCAGGGAGATGTGGGGAAGGGTATTCTAGA 28276
Qy 41 AspAlaThrCysAsnCysAspTyrAsnCysGlnHisTyrMetGluCysCysProAspPhe 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28277 GATGCCACCTGCAACTGTGATTATAACTGTCAACACTACATGGAGTGCTGCCCTGATTTC 28336
Qy 61 LysArgValCysThrAlaGluLeuSerCysLysGlyArgCysPheGluSerPheGluArg 80
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28337 AAGAGAGTCTGCACTGCGGAGCTTTCCTGTAAAGGCCGCTGCTTTGAGTCCTTCGAGAGA 28396
Qy 81 GlyArgGluCysAspCysAspAlaGlnCysLysLysTyrAspLysCysCysProAspTyr 100
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28397 GGGAGGGAGTGTGACTGCGACGCCCAATGTAAGAAGTATGACAAGTGCTGTCCCGATTAT 28456
Qy 101 GluSerPheCysAlaGluValHisAsnProThrSerProProSerSerLysLysAlaPro 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28457 GAGAGTTTCTGTGCAGAAGTGCATAATCCCACATCACCACCATCTTCAAAGAAAGCACCT 28516
Qy 121 ProProSerGlyAlaSerGlnThrIleLysSerThrThrLysArgSerProLysProPro 140
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28517 CCACCTTCAGGAGCATCTCAAACCATCAAATCAACAACCAAACGTTCACCCAAACCACCA 28576
Qy 141 AsnLysLysLysThrLysLysValIleGluSerGluGluIleThrGluGluHisSerVal 160
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28577 AACAAGAAGAAGACTAAGAAAGTTATAGAATCAGAGGAAATAACAGAAGAACATTCTGTT 28636
Qy 161 SerGluAsnGlnGluSerSerSerSerSerSerSerSerSerSerSerSerThrIleArg 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28637 TCTGAAAATCAAGAGTCCTCCTCCTCCTCCTCCTCTTCCTCTTCTTCTTCAACAATTCGG 28696
Qy 181 LysIleLysSerSerLysAsnSerAlaAlaAsnArgGluLeuGlnLysLysLeuLysVal 200
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28697 AAAATCAAGTCTTCCAAAAATTCAGCTGCTAATAGAGAATTACAGAAGAAACTCAAAGTA 28756
Qy 201 LysAspAsnLysLysAsnArgThrLysLysLysProThrProLysProProValValAsp 220
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28757 AAAGATAACAAGAAGAACAGAACTAAAAAGAAACCTACCCCCAAACCACCAGTTGTAGAT 28816
Qy 221 GluAlaGlySerGlyLeuAspAsnGlyAspPheLysValThrThrProAspThrSerThr 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28817 GAAGCTGGAAGTGGATTGGACAATGGTGACTTCAAGGTCACAACTCCTGACACGTCTACC 28876
Qy 241 ThrGlnHisAsnLysValSerThrSerProLysIleThrThrAlaLysProIleAsnPro 260
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28877 ACCCAACACAATAAAGTCAGCACATCTCCCAAGATCACAACAGCAAAACCAATAAATCCC 28936
Qy 261 ArgProSerLeuProProAsnSerAspThrSerLysGluThrSerLeuThrValAsnLys 280
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28937 AGACCCAGTCTTCCACCTAATTCTGATACATCTAAAGAGACGTCTTTGACAGTGAATAAA 28996
Qy 281 GluThrThrValGluThrLysGluThrThrThrThrAsnLysGlnThrSerThrAspGly 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 28997 GAGACAACAGTTGAAACTAAAGAAACTACTACAACAAATAAACAGACTTCAACTGATGGA 29056
Qy 301 LysGluLysThrThrSerAlaLysGluThrGlnSerIleGluLysThrSerAlaLysAsp 320
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 29057 AAAGAGAAGACTACTTCCGCTAAAGAGACACAAAGTATAGAGAAAACATCTGCTAAAGAT 29116
Qy 321 LeuAlaProThrSerLysValLeuAlaLysProThrProLysAlaGluThrThrThrLys 340
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 29117 TTAGCACCCACATCTAAAGTGCTGGCTAAACCTACACCCAAAGCTGAAACTACAACCAAA 29176
Qy 341 GlyProAlaLeuThrThrProLysGluProThrProThrThrProLysGluProAlaSer 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 29177 GGCCCTGCTCTCACCACTCCCAAGGAGCCCACGCCCACCACTCCCAAGGAGCCTGCATCT 29236
Qy 361 ThrThrProLysGluProThrProThrThrIleLysSerAlaProThrThrProLysGlu 380
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 29237 ACCACACCCAAAGAGCCCACACCTACCACCATCAAGTCTGCACCCACCACCCCCAAGGAG 29296
Qy 381 ProAlaProThrThrThrLysSerAlaProThrThrProLysGluProAlaProThrThr 400
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 29297 CCTGCACCCACCACCACCAAGTCTGCACCCACCACTCCCAAGGAGCCTGCACCCACCACC 29356
Qy 401 ThrLysGluProAlaProThrThrProLysGluProAlaProThrThrThrLysGluPro 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 29357 ACCAAGGAGCCTGCACCCACCACTCCCAAGGAGCCTGCACCCACCACCACCAAGGAGCCT 29416
Qy 421 AlaProThrThrThrLysSerAlaProThrThrProLysGluProAlaProThrThrPro 440
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 29417 GCACCCACCACCACCAAGTCTGCACCCACCACTCCCAAGGAGCCTGCACCCACCACCCCC 29476
Qy 441 LysLysProAlaProThrThrProLysGluProAlaProThrThrProLysGluProThr 460
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 29477 AAGAAGCCTGCCCCAACTACCCCCAAGGAGCCTGCACCCACCACTCCCAAGGAGCCTACA 29536
Qy 461 ProThrThrProLysGluProAlaProThrThrLysGluProAlaProThrThrProLys 480
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 29537 CCCACCACTCCCAAGGAGCCTGCACCCACCACCAAGGAGCCTGCACCCACCACTCCCAAA 29596
Qy 481 GluProAlaProThrAlaProLysLysProAlaProThrThrProLysGluProAlaPro 500
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 29597 GAGCCTGCACCCACTGCCCCCAAGAAGCCTGCCCCAACTACCCCCAAGGAGCCTGCACCC 29656
Qy 501 ThrThrProLysGluProAlaProThrThrThrLysGluProSerProThrThrProLys 520
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 29657 ACCACTCCCAAGGAGCCTGCACCCACCACCACCAAGGAGCCTTCACCCACCACTCCCAAG 29716
Qy 521 GluProAlaProThrThrThrLysSerAlaProThrThrThrLysGluProAlaProThr 540
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 29717 GAGCCTGCACCCACCACCACCAAGTCTGCACCCACCACTACCAAGGAGCCTGCACCCACC 29776
Qy 541 ThrThrLysSerAlaProThrThrProLysGluProSerProThrThrThrLysGluPro 560
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 29777 ACTACCAAGTCTGCACCCACCACTCCCAAGGAGCCTTCACCCACCACCACCAAGGAGCCT 29836
Qy 561 AlaProThrThrProLysGluProAlaProThrThrProLysLysProAlaProThrThr 580
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 29837 GCACCCACCACTCCCAAGGAGCCTGCACCCACCACCCCCAAGAAGCCTGCCCCAACTACC 29896
Qy 581 ProLysGluProAlaProThrThrProLysGluProAlaProThrThrThrLysLysPro 600
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 29897 CCCAAGGAGCCTGCACCCACCACTCCCAAGGAACCTGCACCCACCACCACCAAGAAGCCT 29956
Qy 601 AlaProThrThrProLysGluProAlaProThrThrProLysGluThrAlaProThrThr 620
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 29957 GCACCCACCACTCCCAAAGAGCCTGCCCCAACTACCCCCAAGGAGACTGCACCCACCACC 30016
Qy 621 ProLysLysLeuThrProThrThrProGluLysLeuAlaProThrThrProGluLysPro 640
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 30017 CCCAAGAAGCTCACGCCCACCACCCCCGAGAAGCTCGCACCCACCACCCCTGAGAAGCCC 30076
Qy 641 AlaProThrThrProGluGluLeuAlaProThrThrProGluGluProThrProThrThr 660
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 30077 GCACCCACCACCCCTGAGGAGCTCGCACCCACCACCCCTGAGGAGCCCACACCCACCACC 30136
Qy 661 ProGluGluProAlaProThrThrProLysAlaAlaAlaProAsnThrProLysGluPro 680
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 30137 CCTGAGGAGCCTGCTCCCACCACTCCCAAGGCAGCGGCTCCCAACACCCCTAAGGAGCCT 30196
Qy 681 AlaProThrThrProLysGluProAlaProThrThrProLysGluProAlaProThrThr 700
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 30197 GCTCCAACTACCCCTAAGGAGCCTGCTCCAACTACCCCTAAGGAGCCTGCTCCAACTACC 30256
Qy 701 ProLysGluThrAlaProThrThrProLysGlyThrAlaProThrThrLeuLysGluPro 720
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 30257 CCTAAGGAGACTGCTCCAACTACCCCTAAAGGGACTGCTCCAACTACCCTCAAGGAACCT 30316
Qy 721 AlaProThrThrProLysLysProAlaProLysGluLeuAlaProThrThrThrLysGlu 740
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 30317 GCACCCACTACTCCCAAGAAGCCTGCCCCCAAGGAGCTTGCACCCACCACCACCAAGGAG 30376
Qy 741 ProThrSerThrThrSerAspLysProAlaProThrThrProLysGlyThrAlaProThr 760
||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||
Db 30377 CCCACATCCACCACCTGTGACAAGCCCGCTCCAACTACCCCTAAGGGGACTGCTCCAACT 30436
Qy 761 ThrProLysGluProAlaProThrThrProLysGluProAlaProThrThrProLysGly 780
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 30437 ACCCCTAAGGAGCCTGCTCCAACTACCCCTAAGGAGCCTGCTCCAACTACCCCTAAGGGG 30496
Qy 781 ThrAlaProThrThrLeuLysGluProAlaProThrThrProLysLysProAlaProLys 800
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 30497 ACTGCTCCAACTACCCTCAAGGAACCTGCACCCACTACTCCCAAGAAGCCTGCCCCCAAG 30556
Qy 801 GluLeuAlaProThrThrThrLysGlyProThrSerThrThrSerAspLysProAlaPro 820
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 30557 GAGCTTGCACCCACCACCACCAAGGGGCCCACATCCACCACCTCTGACAAGCCTGCTCCA 30616
Qy 821 ThrThrProLysGluThrAlaProThrThrProLysGluProAlaProThrThrProLys 840
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 30617 ACTACACCTAAGGAGACTGCTCCAACTACCCCCAAGGAGCCTGCACCCACTACCCCCAAG 30676
Qy 841 LysProAlaProThrThrProGluThrProProProThrThrSerGluValSerThrPro 860
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 30677 AAGCCTGCTCCAACTACTCCTGAGACACCTCCTCCAACCACTTCAGAGGTCTCTACTCCA 30736
Qy 861 ThrThrThrLysGluProThrThrIleHisLysSerProAspGluSerThrProGluLeu 880
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 30737 ACTACCACCAAGGAGCCTACCACTATCCACAAAAGCCCTGATGAATCAACTCCTGAGCTT 30796
Qy 881 SerAlaGluProThrProLysAlaLeuGluAsnSerProLysGluProGlyValProThr 900
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 30797 TCTGCAGAACCCACACCAAAAGCTCTTGAAAACAGTCCCAAGGAACCTGGTGTACCTACA 30856
Qy 901 ThrLysThrProAlaAlaThrLysProGluMetThrThrThrAlaLysAspLysThrThr 920
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 30857 ACTAAGACTCCTGCAGCGACTAAACCTGAAATGACTACAACAGCTAAAGACAAGACAACA 30916
Qy 921 GluArgAspLeuArgThrThrProGluThrThrThrAlaAlaProLysMetThrLysGlu 940
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 30917 GAAAGAGACTTACGTACTACACCTGAAACTACAACTGCTGCACCTAAGATGACAAAAGAG 30976
Qy 941 ThrAlaThrThrThrGluLysThrThrGluSerLysIleThrAlaThrThrThrGlnVal 960
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 30977 ACAGCAACTACAACAGAAAAAACTACCGAATCCAAAATAACAGCTACAACCACACAAGTA 31036
Qy 961 ThrSerThrThrThrGlnAspThrThrProPheLysIleThrThrLeuLysThrThrThr 980
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31037 ACATCTACCACAACTCAAGATACCACACCATTCAAAATTACTACTCTTAAAACAACTACT 31096
Qy 981 LeuAlaProLysValThrThrThrLysLysThrIleThrThrThrGluIleMetAsnLys 1000
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31097 CTTGCACCCAAAGTAACTACAACAAAAAAGACAATTACTACCACTGAGATTATGAACAAA 31156
Qy 1001 ProGluGluThrAlaLysProLysAspArgAlaThrAsnSerLysAlaThrThrProLys 1020
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31157 CCTGAAGAAACAGCTAAACCAAAAGACAGAGCTACTAATTCTAAAGCGACAACTCCTAAA 31216
Qy 1021 ProGlnLysProThrLysAlaProLysLysProThrSerThrLysLysProLysThrMet 1040
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31217 CCTCAAAAGCCAACCAAAGCACCCAAAAAACCCACTTCTACCAAAAAGCCAAAAACAATG 31276
Qy 1041 ProArgValArgLysProLysThrThrProThrProArgLysMetThrSerThrMetPro 1060
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31277 CCTAGAGTGAGAAAACCAAAGACGACACCAACTCCCCGCAAGATGACATCAACAATGCCA 31336
Qy 1061 GluLeuAsnProThrSerArgIleAlaGluAlaMetLeuGlnThrThrThrArgProAsn 1080
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31337 GAATTGAACCCTACCTCAAGAATAGCAGAAGCCATGCTCCAAACCACCACCAGACCTAAC 31396
Qy 1081 GlnThrProAsnSerLysLeuValGluValAsnProLysSerGluAspAlaGlyGlyAla 1100
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31397 CAAACTCCAAACTCCAAACTAGTTGAAGTAAATCCAAAGAGTGAAGATGCAGGTGGTGCT 31456
Qy 1101 GluGlyGluThrProHisMetLeuLeuArgProHisValPheMetProGluValThrPro 1120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31457 GAAGGAGAAACACCTCATATGCTTCTCAGGCCCCATGTGTTCATGCCTGAAGTTACTCCC 31516
Qy 1121 AspMetAspTyrLeuProArgValProAsnGlnGlyIleIleIleAsnProMetLeuSer 1140
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31517 GACATGGATTACTTACCGAGAGTACCCAATCAAGGCATTATCATCAATCCCATGCTTTCC 31576
Qy 1141 AspGluThrAsnIleCysAsnGlyLysProValAspGlyLeuThrThrLeuArgAsnGly 1160
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31577 GATGAGACCAATATATGCAATGGTAAGCCAGTAGATGGACTGACTACTTTGCGCAATGGG 31636
Qy 1161 ThrLeuValAlaPheArgGlyHisTyrPheTrpMetLeuSerProPheSerProProSer 1180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31637 ACATTAGTTGCATTCCGAGGTCATTATTTCTGGATGCTAAGTCCATTCAGTCCACCATCT 31696
Qy 1181 ProAlaArgArgIleThrGluValTrpGlyIleProSerProIleAspThrValPheThr 1200
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31697 CCAGCTCGCAGAATTACTGAAGTTTGGGGTATTCCTTCCCCCATTGATACTGTTTTTACT 31756
Qy 1201 ArgCysAsnCysGluGlyLysThrPhePhePheLysAspSerGlnTyrTrpArgPheThr 1220
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31757 AGGTGCAACTGTGAAGGAAAAACTTTCTTCTTTAAGGATTCTCAGTACTGGCGTTTTACC 31816
Qy 1221 AsnAspIleLysAspAlaGlyTyrProLysProIlePheLysGlyPheGlyGlyLeuThr 1240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31817 AATGATATAAAAGATGCAGGGTACCCCAAACCAATTTTCAAAGGATTTGGAGGACTAACT 31876
Qy 1241 GlyGlnIleValAlaAlaLeuSerThrAlaLysTyrLysAsnTrpProGluSerValTyr 1260
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31877 GGACAAATAGTGGCAGCGCTTTCAACAGCTAAATATAAGAACTGGCCTGAATCTGTGTAT 31936
Qy 1261 PhePheLysArgGlyGlySerIleGlnGlnTyrIleTyrLysGlnGluProValGlnLys 1280
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31937 TTTTTCAAGAGAGGTGGCAGCATTCAGCAGTATATTTATAAACAGGAACCTGTACAGAAG 31996
Qy 1281 CysProGlyArgArgProAlaLeuAsnTyrProValTyrGlyGluThrThrGlnValArg 1300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 31997 TGCCCTGGAAGAAGGCCTGCTCTAAATTATCCAGTGTATGGAGAAACGACACAGGTTAGG 32056
Qy 1301 ArgArgArgPheGluArgAlaIleGlyProSerGlnThrHisThrIleArgIleGlnTyr 1320
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 32057 AGACGTCGCTTTGAACGTGCTATAGGACCTTCTCAAACACACACCATCAGAATTCAATAT 32116
Qy 1321 SerProAlaArgLeuAlaTyrGlnAspLysGlyValLeuHisAsnGluValLysValSer 1340
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 32117 TCACCTGCCAGACTGGCTTATCAAGACAAAGGTGTCCTTCATAATGAAGTTAAAGTGAGT 32176
Qy 1341 IleLeuTrpArgGlyLeuProAsnValValThrSerAlaIleSerLeuProAsnIleArg 1360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 32177 ATACTGTGGAGAGGACTTCCAAATGTGGTTACCTCAGCTATATCACTGCCCAACATCAGA 32236
Qy 1361 LysProAspGlyTyrAspTyrTyrAlaPheSerLysAspGlnTyrTyrAsnIleAspVal 1380
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 32237 AAACCTGACGGCTATGATTACTATGCCTTTTCTAAAGATCAATACTATAACATTGATGTG 32296
Qy 1381 ProSerArgThrAlaArgAlaIleThrThrArgSerGlyGlnThrLeuSerLysValTrp 1400
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 32297 CCTAGTAGAACAGCAAGAGCAATTACTACTCGTTCTGGGCAGACCTTATCCAAAGTCTGG 32356
Qy 1401 TyrAsnCysPro 1404
||||||||||||
Db 32357 TACAACTGTCCT 32368
Sequence 12,
Patent No. 11905531
Human PRG4 transcript variant A nucleic acid sequence
Alignment Scores:
Length: 5050
Score: 7521.00 Matches: 1404
Percent Similarity: 100.0% Conservative: 0
Best Local Similarity: 100.0% Mismatches: 0
Query Match: 100.0% Indels: 0
Gaps: 0
US-17-772-450-1 (1-1404) x US-16-524-645-12 (1-5050)
Qy 1 MetAlaTrpLysThrLeuProIleTyrLeuLeuLeuLeuLeuSerValPheValIleGln 20
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 52 ATGGCATGGAAAACACTTCCCATTTACCTGTTGTTGCTGCTGTCTGTTTTCGTGATTCAG 111
Qy 21 GlnValSerSerGlnAspLeuSerSerCysAlaGlyArgCysGlyGluGlyTyrSerArg 40
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 112 CAAGTTTCATCTCAAGATTTATCAAGCTGTGCAGGGAGATGTGGGGAAGGGTATTCTAGA 171
Qy 41 AspAlaThrCysAsnCysAspTyrAsnCysGlnHisTyrMetGluCysCysProAspPhe 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 172 GATGCCACCTGCAACTGTGATTATAACTGTCAACACTACATGGAGTGCTGCCCTGATTTC 231
Qy 61 LysArgValCysThrAlaGluLeuSerCysLysGlyArgCysPheGluSerPheGluArg 80
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 232 AAGAGAGTCTGCACTGCGGAGCTTTCCTGTAAAGGCCGCTGCTTTGAGTCCTTCGAGAGA 291
Qy 81 GlyArgGluCysAspCysAspAlaGlnCysLysLysTyrAspLysCysCysProAspTyr 100
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 292 GGGAGGGAGTGTGACTGCGACGCCCAATGTAAGAAGTATGACAAGTGCTGTCCCGATTAT 351
Qy 101 GluSerPheCysAlaGluValHisAsnProThrSerProProSerSerLysLysAlaPro 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 352 GAGAGTTTCTGTGCAGAAGTGCATAATCCCACATCACCACCATCTTCAAAGAAAGCACCT 411
Qy 121 ProProSerGlyAlaSerGlnThrIleLysSerThrThrLysArgSerProLysProPro 140
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 412 CCACCTTCAGGAGCATCTCAAACCATCAAATCAACAACCAAACGTTCACCCAAACCACCA 471
Qy 141 AsnLysLysLysThrLysLysValIleGluSerGluGluIleThrGluGluHisSerVal 160
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 472 AACAAGAAGAAGACTAAGAAAGTTATAGAATCAGAGGAAATAACAGAAGAACATTCTGTT 531
Qy 161 SerGluAsnGlnGluSerSerSerSerSerSerSerSerSerSerSerSerThrIleArg 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 532 TCTGAAAATCAAGAGTCCTCCTCCTCCTCCTCCTCTTCCTCTTCTTCTTCAACAATTCGG 591
Qy 181 LysIleLysSerSerLysAsnSerAlaAlaAsnArgGluLeuGlnLysLysLeuLysVal 200
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 592 AAAATCAAGTCTTCCAAAAATTCAGCTGCTAATAGAGAATTACAGAAGAAACTCAAAGTA 651
Qy 201 LysAspAsnLysLysAsnArgThrLysLysLysProThrProLysProProValValAsp 220
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 652 AAAGATAACAAGAAGAACAGAACTAAAAAGAAACCTACCCCCAAACCACCAGTTGTAGAT 711
Qy 221 GluAlaGlySerGlyLeuAspAsnGlyAspPheLysValThrThrProAspThrSerThr 240
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 712 GAAGCTGGAAGTGGATTGGACAATGGTGACTTCAAGGTCACAACTCCTGACACGTCTACC 771
Qy 241 ThrGlnHisAsnLysValSerThrSerProLysIleThrThrAlaLysProIleAsnPro 260
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 772 ACCCAACACAATAAAGTCAGCACATCTCCCAAGATCACAACAGCAAAACCAATAAATCCC 831
Qy 261 ArgProSerLeuProProAsnSerAspThrSerLysGluThrSerLeuThrValAsnLys 280
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 832 AGACCCAGTCTTCCACCTAATTCTGATACATCTAAAGAGACGTCTTTGACAGTGAATAAA 891
Qy 281 GluThrThrValGluThrLysGluThrThrThrThrAsnLysGlnThrSerThrAspGly 300
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 892 GAGACAACAGTTGAAACTAAAGAAACTACTACAACAAATAAACAGACTTCAACTGATGGA 951
Qy 301 LysGluLysThrThrSerAlaLysGluThrGlnSerIleGluLysThrSerAlaLysAsp 320
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 952 AAAGAGAAGACTACTTCCGCTAAAGAGACACAAAGTATAGAGAAAACATCTGCTAAAGAT 1011
Qy 321 LeuAlaProThrSerLysValLeuAlaLysProThrProLysAlaGluThrThrThrLys 340
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1012 TTAGCACCCACATCTAAAGTGCTGGCTAAACCTACACCCAAAGCTGAAACTACAACCAAA 1071
Qy 341 GlyProAlaLeuThrThrProLysGluProThrProThrThrProLysGluProAlaSer 360
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1072 GGCCCTGCTCTCACCACTCCCAAGGAGCCCACGCCCACCACTCCCAAGGAGCCTGCATCT 1131
Qy 361 ThrThrProLysGluProThrProThrThrIleLysSerAlaProThrThrProLysGlu 380
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1132 ACCACACCCAAAGAGCCCACACCTACCACCATCAAGTCTGCACCCACCACCCCCAAGGAG 1191
Qy 381 ProAlaProThrThrThrLysSerAlaProThrThrProLysGluProAlaProThrThr 400
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1192 CCTGCACCCACCACCACCAAGTCTGCACCCACCACTCCCAAGGAGCCTGCACCCACCACC 1251
Qy 401 ThrLysGluProAlaProThrThrProLysGluProAlaProThrThrThrLysGluPro 420
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1252 ACCAAGGAGCCTGCACCCACCACTCCCAAGGAGCCTGCACCCACCACCACCAAGGAGCCT 1311
Qy 421 AlaProThrThrThrLysSerAlaProThrThrProLysGluProAlaProThrThrPro 440
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1312 GCACCCACCACCACCAAGTCTGCACCCACCACTCCCAAGGAGCCTGCACCCACCACCCCC 1371
Qy 441 LysLysProAlaProThrThrProLysGluProAlaProThrThrProLysGluProThr 460
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1372 AAGAAGCCTGCCCCAACTACCCCCAAGGAGCCTGCACCCACCACTCCCAAGGAGCCTACA 1431
Qy 461 ProThrThrProLysGluProAlaProThrThrLysGluProAlaProThrThrProLys 480
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1432 CCCACCACTCCCAAGGAGCCTGCACCCACCACCAAGGAGCCTGCACCCACCACTCCCAAA 1491
Qy 481 GluProAlaProThrAlaProLysLysProAlaProThrThrProLysGluProAlaPro 500
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1492 GAGCCTGCACCCACTGCCCCCAAGAAGCCTGCCCCAACTACCCCCAAGGAGCCTGCACCC 1551
Qy 501 ThrThrProLysGluProAlaProThrThrThrLysGluProSerProThrThrProLys 520
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1552 ACCACTCCCAAGGAGCCTGCACCCACCACCACCAAGGAGCCTTCACCCACCACTCCCAAG 1611
Qy 521 GluProAlaProThrThrThrLysSerAlaProThrThrThrLysGluProAlaProThr 540
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1612 GAGCCTGCACCCACCACCACCAAGTCTGCACCCACCACTACCAAGGAGCCTGCACCCACC 1671
Qy 541 ThrThrLysSerAlaProThrThrProLysGluProSerProThrThrThrLysGluPro 560
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1672 ACTACCAAGTCTGCACCCACCACTCCCAAGGAGCCTTCACCCACCACCACCAAGGAGCCT 1731
Qy 561 AlaProThrThrProLysGluProAlaProThrThrProLysLysProAlaProThrThr 580
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1732 GCACCCACCACTCCCAAGGAGCCTGCACCCACCACCCCCAAGAAGCCTGCCCCAACTACC 1791
Qy 581 ProLysGluProAlaProThrThrProLysGluProAlaProThrThrThrLysLysPro 600
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1792 CCCAAGGAGCCTGCACCCACCACTCCCAAGGAACCTGCACCCACCACCACCAAGAAGCCT 1851
Qy 601 AlaProThrThrProLysGluProAlaProThrThrProLysGluThrAlaProThrThr 620
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1852 GCACCCACCACTCCCAAAGAGCCTGCCCCAACTACCCCCAAGGAGACTGCACCCACCACC 1911
Qy 621 ProLysLysLeuThrProThrThrProGluLysLeuAlaProThrThrProGluLysPro 640
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1912 CCCAAGAAGCTCACGCCCACCACCCCCGAGAAGCTCGCACCCACCACCCCTGAGAAGCCC 1971
Qy 641 AlaProThrThrProGluGluLeuAlaProThrThrProGluGluProThrProThrThr 660
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1972 GCACCCACCACCCCTGAGGAGCTCGCACCCACCACCCCTGAGGAGCCCACACCCACCACC 2031
Qy 661 ProGluGluProAlaProThrThrProLysAlaAlaAlaProAsnThrProLysGluPro 680
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2032 CCTGAGGAGCCTGCTCCCACCACTCCCAAGGCAGCGGCTCCCAACACCCCTAAGGAGCCT 2091
Qy 681 AlaProThrThrProLysGluProAlaProThrThrProLysGluProAlaProThrThr 700
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2092 GCTCCAACTACCCCTAAGGAGCCTGCTCCAACTACCCCTAAGGAGCCTGCTCCAACTACC 2151
Qy 701 ProLysGluThrAlaProThrThrProLysGlyThrAlaProThrThrLeuLysGluPro 720
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2152 CCTAAGGAGACTGCTCCAACTACCCCTAAAGGGACTGCTCCAACTACCCTCAAGGAACCT 2211
Qy 721 AlaProThrThrProLysLysProAlaProLysGluLeuAlaProThrThrThrLysGlu 740
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 2212 GCACCCACTACTCCCAAGAAGCCTGCCCCCAAGGAGCTTGCACCCACCACCACCAAGGAG 2271
Qy 741 ProThrSerThrThrSerAspLysProAlaProTh